{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:44:52Z","timestamp":1776721492760,"version":"3.51.2"},"reference-count":12,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Antecedentes: La dermatitis at\u00f3pica es una enfermedad inflamatoria cr\u00f3nica que afecta la piel y se caracteriza por prurito intenso y eccema.Requiere de terapias sist\u00e9micas y el uso de tratamientos novedosos, como Dupilumab o inhibidores de Janus Kinasa. La aprobaci\u00f3n de estos medicamentos ha venido a revolucionar el tratamiento en los \u00faltimos a\u00f1os.\nReporte de caso: Se expone el caso de paciente masculino de 22 a\u00f1os, con dermatitis at\u00f3pica grave, resistente al tratamiento con inmunosupresor y su evoluci\u00f3n al iniciar el cambio con anticuerpos monoclonales.\nConclusiones: Los anticuerpos monoclonales son terapias avanzadas y novedosas que han demostrado eficacia en pacientes con dermatitis at\u00f3pica moderada a grave. En este art\u00edculo presentamos el caso de un paciente que, con cambio de mol\u00e9cula, presenta mejor\u00eda en su evoluci\u00f3n y calidad de vida, demostrando una adecuada respuesta de acuerdo con el \u00edndice de puntuaci\u00f3n de dermatitis (SCORAD) tras manejo con Abrocitinib.\nPalabras clave: Dermatitis at\u00f3pica; Anticuerpos monoclonales; Dupilumab; Abrocitinib; Inmunosupresores.<\/jats:p>","DOI":"10.29262\/ram.v72i4.1547","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:36:56Z","timestamp":1767829016000},"page":"382-385","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Experiencia en el cambio de un anticuerpo monoclonal en un paciente con dermatitis at\u00f3pica grave resistente al tratamiento convencional: de dupilumab a abrocitinib. Reporte de un caso &lt;\/b&gt;","&lt;b&gt;Experience in switching monoclonal antibodies in a patient with severe refractory atopic dermatitis: from Dupilumab to Abrocitinib. Case report &lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7419-9487","authenticated-orcid":false,"given":"Ariadna","family":"Palafox Olvera","sequence":"first","affiliation":[{"name":"Hospital Ju\u00e1rez de M\u00e9xico, Ciudad de M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-3991","authenticated-orcid":false,"given":"Carol Vivian","family":"Moncayo Coello","sequence":"additional","affiliation":[{"name":"Hospital Ju\u00e1rez de M\u00e9xico, Ciudad de M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-7071","authenticated-orcid":false,"given":"Gloria","family":"Castillo Narva\u00e9z","sequence":"additional","affiliation":[{"name":"Hospital Ju\u00e1rez de M\u00e9xico, Ciudad de M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"65519","doi-asserted-by":"crossref","unstructured":"1. Simpson EL, Silverberg JI, Thyssen JP, et al. Efficacy and Safety of Abrocitinib in Patients with Severe and\/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial. Am J Clin Dermatol 2023; 24 (4): 609-621. doi: 10.1007\/s40257-023-00785-5","DOI":"10.1007\/s40257-023-00785-5"},{"key":"65520","doi-asserted-by":"crossref","unstructured":"2. Perche PO, Cook MK, Feldman SR. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. Ann Pharmacother 2023; 57 (1): 86-98. doi: 10.1177\/10600280221096713Doi:10.3310\/LEXB9006.","DOI":"10.1177\/10600280221096713"},{"key":"65521","doi-asserted-by":"crossref","unstructured":"3. Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35 (9): 1797-1810. doi: 10.1111\/jdv.17351","DOI":"10.1111\/jdv.17351"},{"key":"65522","doi-asserted-by":"crossref","unstructured":"4. Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. Am J Clin Dermatol 2020; 21 (6): 783-798. doi: 10.1007\/s40257-020-00548-6","DOI":"10.1007\/s40257-020-00548-6"},{"key":"65523","doi-asserted-by":"crossref","unstructured":"5. Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of Abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. Dermatol Ther. 2022; 35 (9): e15636. doi: 10.1111\/dth.15636","DOI":"10.1111\/dth.15636"},{"key":"65524","doi-asserted-by":"crossref","unstructured":"6. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol 2022; 158 (5): 523-532. doi: 10.1001\/jamadermatol.2022.0455","DOI":"10.1001\/jamadermatol.2022.0455"},{"key":"65525","doi-asserted-by":"crossref","unstructured":"7. Tsai YC, Tsai TF. Successful treatment of atopic dermatitis by switching from upadacitinib to Abrocitinib: a case report. Eur J Dermatol 2023; 33 (6): 699-701. doi: 10.1684\/ejd.2023.4581","DOI":"10.1684\/ejd.2023.4581"},{"key":"65526","doi-asserted-by":"crossref","unstructured":"8. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024; 90 (2): e43-e56. doi: 10.1016\/j.jaad.2023.08.102","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"65527","doi-asserted-by":"crossref","unstructured":"9. Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, et al. Abrocitinib versus placebo or Dupilumab for atopic dermatitis. N Engl J Med 2021; 384 (12): 1101-12","DOI":"10.1056\/NEJMoa2019380"},{"key":"65528","doi-asserted-by":"crossref","unstructured":"10. AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol 2024; 132 (3): 274-312. doi: 10.1016\/j.anai.2023.11.009","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"65529","doi-asserted-by":"crossref","unstructured":"11. Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of Abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from Dupilumab (JADE EXTEND). J Am Acad Dermatol 2022; 87 (2): 351-358. doi: 10.1016\/j.jaad.2022.04.009","DOI":"10.1016\/j.jaad.2022.04.009"},{"key":"65530","doi-asserted-by":"crossref","unstructured":"12. Lasheras-P\u00e9rez MA, Palacios-D\u00edaz RD, Pozuelo-Ru\u00edz M, Torres-Navarro I, et al. Switching from Dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol 2024; 63 (1): 105-107.","DOI":"10.1111\/ijd.16926"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1547\/2800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1547\/2823","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1547\/2800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:56:56Z","timestamp":1776718616000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i4.1547","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}